3 results
The primary objectives are to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RP2D) of ABBV-621 and to evaluate pharmacokinetics (PK) of (A) single agent ABBV-621; and (B) the combination of ABBV-621 and venetoclax in…
The purpose of the study is to investigate to what extent DA-3880 is absorbed and eliminated from the body (this is called pharmacokinetics) as compared to the above mentioned Aranesp® formulation. In addition, the effect DA-3880 on the number of…
The objective of this study is to determine user perception of the 2-piece flat skin barrier compared to the current Dansac flat 2-piece barrier, specifically as it relates to barrier adhesion, barrier tack, comfort, leakage, and ease of barrier…